4.6 Article

Effect of intravenous cell therapy in rats with old myocardial infarction

Journal

MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 477, Issue 2, Pages 431-444

Publisher

SPRINGER
DOI: 10.1007/s11010-021-04283-2

Keywords

Cell therapy; Stem cells; Fibrosis; Inflammation; Intravenous; Ischemic cardiomyopathy; Myocardial infarction; Repair

Categories

Funding

  1. NIH [HL113530, HL-078825]

Ask authors/readers for more resources

The study showed that a single intravenous administration of three types of cells in rats with chronic ischemic cardiomyopathy effectively attenuated the progressive deterioration in LV function. Among the three cell types, CPCs demonstrated the greatest improvement in LV functional status, followed by CMCs and then MSCs.
Mounting evidence shows that cell therapy provides therapeutic benefits in experimental and clinical settings of chronic heart failure. However, direct cardiac delivery of cells via transendocardial injection is logistically complex, expensive, entails risks, and is not amenable to multiple dosing. Intravenous administration would be a more convenient and clinically applicable route for cell therapy. Thus, we determined whether intravenous infusion of three widely used cell types improves left ventricular (LV) function and structure and compared their efficacy. Rats with a 30-day-old myocardial infarction (MI) received intravenous infusion of vehicle (PBS) or 1 of 3 types of cells: bone marrow mesenchymal stromal cells (MSCs), cardiac mesenchymal cells (CMCs), and c-kit-positive cardiac cells (CPCs), at a dose of 12 x 10(6) cells. Rats were followed for 35 days after treatment to determine LV functional status by serial echocardiography and hemodynamic studies. Blood samples were collected for Hemavet analysis to determine inflammatory cell profile. LV ejection fraction (EF) dropped >= 20 points in all hearts at 30 days after MI and deteriorated further at 35-day follow-up in the vehicle-treated group. In contrast, deterioration of EF was halted in rats that received MSCs and attenuated in those that received CMCs or CPCs. None of the 3 types of cells significantly altered scar size, myocardial content of collagen or CD45-positive cells, or Hemavet profile. This study demonstrates that a single intravenous administration of 3 types of cells in rats with chronic ischemic cardiomyopathy is effective in attenuating the progressive deterioration in LV function. The extent of LV functional improvement was greatest with CPCs, intermediate with CMCs, and least with MSCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available